Avalo Therapeutics, Inc. (AVTX)
19.26
-0.57
(-2.87%)
USD |
NASDAQ |
Aug 24, 16:00
19.26
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics Shareholders Equity (Quarterly) : 448.66M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 448.66M |
| March 31, 2026 | 68.32M |
| December 31, 2025 | 83.05M |
| September 30, 2025 | 91.55M |
| June 30, 2025 | 104.57M |
| March 31, 2025 | 122.62M |
| December 31, 2024 | 133.03M |
| September 30, 2024 | 22.73M |
| June 30, 2024 | -2.151M |
| March 31, 2024 | -101.08M |
| December 31, 2023 | 7.304M |
| September 30, 2023 | 14.70M |
| June 30, 2023 | -6.969M |
| March 31, 2023 | -6.267M |
| December 31, 2022 | -10.92M |
| September 30, 2022 | -2.028M |
| June 30, 2022 | -5.951M |
| March 31, 2022 | 6.343M |
| December 31, 2021 | 23.08M |
| September 30, 2021 | 40.31M |
| June 30, 2021 | 21.59M |
| March 31, 2021 | 33.16M |
| December 31, 2020 | 24.56M |
| Date | Value |
|---|---|
| September 30, 2020 | 38.57M |
| June 30, 2020 | 50.58M |
| March 31, 2020 | 25.59M |
| December 31, 2019 | |
| September 30, 2019 | 18.22M |
| June 30, 2019 | 17.70M |
| March 31, 2019 | 23.12M |
| December 31, 2018 | 20.91M |
| September 30, 2018 | 19.51M |
| June 30, 2018 | 19.22M |
| March 31, 2018 | 24.58M |
| December 31, 2017 | 27.86M |
| September 30, 2017 | 22.12M |
| June 30, 2017 | 3.136M |
| March 31, 2017 | -0.4258M |
| December 31, 2016 | 0.207M |
| September 30, 2016 | 0.5868M |
| June 30, 2016 | 5.571M |
| March 31, 2016 | 8.881M |
| December 31, 2015 | 13.08M |
| September 30, 2015 | -4.505M |
| June 30, 2015 | -3.843M |
| March 31, 2015 | -1.173M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Incyte Corp. | 6.344B |
| AbbVie, Inc. | -5.935B |
| Rezolute, Inc. | 116.83M |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 490.78M |
| Total Liabilities (Quarterly) | 42.12M |
| Debt to Equity Ratio | 0.005 |
| Current Ratio | 19.31 |
| Net Debt Paydown Yield | 0.01% |